Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 4/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.34 |
| ▸ | UGCG | Q16739 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | CBLB | Q13191 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | MYLK | Q15746 | 1/20 | 0.31 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24003850 | 0.94 | MAPK14 (0.40) | CYP11B1CYP11B2JAK2PIK3CGMAPK14 | |
| SCHEMBL25822707 | 0.90 | CYP11B2 (0.37) | CYP11B1CYP11B2JAK2PIK3CGMAPK14 | |
| SCHEMBL26328138 | 0.90 | CYP11B1 (0.35) | CYP11B1CYP11B2JAK2PIK3CGMAPK14 | |
| SCHEMBL25822372 | 0.89 | MAPK14 (0.46) | MAPK14 | |
| SCHEMBL24003825 | 0.88 | MAPK14 (0.41) | CYP11B1CYP11B2JAK2PIK3CGMAPK14 | |
| SCHEMBL25185237 | 0.88 | CYP11B2 (0.42) | CYP11B1CYP11B2JAK2PIK3CGUGCG | |
| SCHEMBL24003831 | 0.86 | TDO2 (0.39) | CYP11B1CYP11B2PIK3CGMAPK14UGCG | |
| SCHEMBL30232661 | 0.86 | CYP11B2 (0.38) | CYP11B1CYP11B2PIK3CGMAPK14UGCG | |
| SCHEMBL30232709 | 0.86 | TDO2 (0.39) | CYP11B1CYP11B2PIK3CGMAPK14UGCG | |
| SCHEMBL24004082 | 0.86 | CYP11B2 (0.38) | CYP11B1CYP11B2PIK3CGMAPK14UGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | CYP11B1 587/4885CYP11B2 858/4885JAK2 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.